Pfizer India
Riding the brandwagon; Initiating with a Buy
Continued support from a strong parent and brand equity are Pfizer’s
backbone. Focus on expanding branded generics business in emerging
markets and higher productivity on account of field force addition in
past two years are key growth drivers, going forward. Further, the
company’s strong cash position is sure to give it enough leverage to
grow the inorganic way. Thus, we initiate coverage on Pfizer with a
Buy rating and price target of `1,518.